Viking Therapeutics Announces Results from Phase 1b Clinical ...
WEB1 day ago · Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
Viking Therapeutics Announces Results from Phase 1b Clinical ...
WEB2 days ago · SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the ...
Viking Therapeutics' stock pops on news of positive data from ...
WEB1 day ago · Viking Therapeutics Inc.'s stock (VKTX) rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare and often fatal ...
Viking Therapeutics reports positive data from trial of ...
WEB1 day ago · Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic disorder X-linked adrenoleukodystrophy, or X-ALD. San ...
Viking Therapeutics Reports Positive Data From Phase 1b Study ...
WEB1 day ago · Oct. 9, 2024, 07:36 AM. (RTTNews) - Viking Therapeutics, Inc. (VKTX), Wednesday announced positive data from Phase 1b study of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). X-ALD ...
Viking Therapeutics - Press Releases
WEBJul 24, 2024 · Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association. Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO ...
News & Events - Viking Therapeutics InvestorRoom
WEBFeb 27, 2024 · Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity. Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo.
Viking to charge quickly into phase 3 with obesity med
WEBJul 25, 2024 · Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million.
Buy Rating Affirmed for Viking Therapeutics as VK2735 Shows ...
WEBSep 30, 2024 · Michael Ulz has given his Buy rating due to a combination of factors surrounding Viking Therapeutics’ VK2735, an oral medication being developed to treat obesity.
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote ...
WEBFind the latest Viking Therapeutics, Inc. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
- Some results have been removed